Neurologic complications of HIV infection: Highlights from the 2013 conference on retroviruses and opportunistic infections

Topics in Antiviral Medicine

Volumn 21, Issue 3, 2013, Pages 100-108

  Spudich, Serena S ^a   Ances, Beau M ^b  

^a YALE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Central nervous system; Dementia; HAND; HIV; HIV associated neurocognitive disorder; Neuroimaging; Neurology; Neuropathy

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; MARAVIROC; NATALIZUMAB; RALTEGRAVIR; RITONAVIR; TENOFOVIR;

ARTICLE; CD8+ T LYMPHOCYTE; DAILY LIFE ACTIVITY; DIFFUSION TENSOR IMAGING; DISEASE ERADICATION; DRUG EFFICACY; DRUG SAFETY; FATTY LIVER; FOLLOW UP; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; MORBIDITY; NEUROIMAGING; NEUROLOGICAL COMPLICATION; OPPORTUNISTIC INFECTION; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROVIRUS INFECTION; SCORING SYSTEM; TREATMENT OUTCOME;

DELAYED DIAGNOSIS; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; NERVOUS SYSTEM DISEASES;

EID: 84882997938     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819-1825.
2. Edén A, Hagberg L, Svennerholm B, Price R, Gisslen M. Longitudinal follow up of detectable HIV-1 RNA in cerebrospinal fluid in subjects on suppressive ART [Abstract 488]. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2013; Seattle, Washington.
3. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration- effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65-70.
4. Braithwaite RS, Justice AC, Chang CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118(8):890-898.
5. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63(5):822-827.
6. Scott JC, Woods SP, Carey CL, Weber E, Bondi MW, Grant I. Neurocognitive consequences of HIV infection in older adults: an evaluation of the cortical hypothesis. AIDS Behav. 2011;15(6):1187-1196.
7. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3-16.
8. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157(1- 2):197-202.
9. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78(7):485-492.
10. Foley J, Ettenhofer M, Wright MJ, et al. Neurocognitive functioning in HIV- 1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol. 2010;24(2):265-285.
11. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773-778.
12. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765-1774.